Subscribe
man_at_mouse
man_at_mouse / iStockphoto.com
7 February 2019Biotechnology

Victory for Mayo in neurological disorder patent dispute

In a victory for Mayo Collaborative Services, a US Court has ruled that four claims in a patent, of which Athena Diagnostics is the exclusive licensee, are invalid.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Federal Circuit refuses to rehear Athena dispute; judges call for reform
4 July 2019   The US Court of Appeals for the Federal Circuit has upheld a win for Mayo Collaborative Services after it denied Athena Diagnostics’ petition to have a neurological patent dispute reheard en banc.
Big Pharma
Athena asks for rehearing on invalidated neurological disorder patent
9 April 2019   Athena Diagnostics has asked the US Federal Circuit to revisit its decision earlier this year, which found four claims in one of its patents to be invalid.
Americas
Amerigen loses patent case against UCB at Federal Circuit
14 January 2019   US-based Amerigen Pharmaceuticals has lost in its bid to prove that claims in a patent owned by biopharmaceutical company UCB were covered by a prior invention.


Editor's picks

Astellas win strengthens blockbuster drug's European position
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025

Editor's picks

Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025
Americas
Latham steps into dispute over $6bn treatment, replacing Kirkland
13 August 2025
Americas
BMS blocks biosimilar version of blockbuster cancer drug in India
21 July 2025
Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025
Africa
Explainer: ARIPO’s role in Plant Variety Protection
15 July 2025
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

More on this story

Americas
Federal Circuit refuses to rehear Athena dispute; judges call for reform
4 July 2019   The US Court of Appeals for the Federal Circuit has upheld a win for Mayo Collaborative Services after it denied Athena Diagnostics’ petition to have a neurological patent dispute reheard en banc.
Big Pharma
Athena asks for rehearing on invalidated neurological disorder patent
9 April 2019   Athena Diagnostics has asked the US Federal Circuit to revisit its decision earlier this year, which found four claims in one of its patents to be invalid.
Americas
Amerigen loses patent case against UCB at Federal Circuit
14 January 2019   US-based Amerigen Pharmaceuticals has lost in its bid to prove that claims in a patent owned by biopharmaceutical company UCB were covered by a prior invention.

More on this story

Americas
Federal Circuit refuses to rehear Athena dispute; judges call for reform
4 July 2019   The US Court of Appeals for the Federal Circuit has upheld a win for Mayo Collaborative Services after it denied Athena Diagnostics’ petition to have a neurological patent dispute reheard en banc.
Big Pharma
Athena asks for rehearing on invalidated neurological disorder patent
9 April 2019   Athena Diagnostics has asked the US Federal Circuit to revisit its decision earlier this year, which found four claims in one of its patents to be invalid.
Americas
Amerigen loses patent case against UCB at Federal Circuit
14 January 2019   US-based Amerigen Pharmaceuticals has lost in its bid to prove that claims in a patent owned by biopharmaceutical company UCB were covered by a prior invention.

More features

The rise of pro-NPE and patent sentiment in the US
UPC sees rising small molecule litigation with Pfizer in the hot seat
Why the Caribbean cannabis economy is ripe for IP protection
China filings push rise in patent applications in Ireland
Brain disorder medtech rivals butt heads at ITC
‘This is not a rescue deal’: How an acquisition fits London firm's plan
Alston & Bird partner with strong Japanese ties jumps to new firm
Chinese invisible braces maker hits back at infringement claims